Restoring vision

61.5% of patients improve vision by ≥10 letters within 2 months.

Download presentation

Age-related macular degeneration (AMD) affects central vision

Dry AMD is a chronic disease of the macula (the central retina) that gradually reduces central vision over time. Intermediate AMD is the first stage of the disease to experience vision loss.

1 in 4 people

are affected by AMD and it is the leading cause of blindness in those over age 60.

US population for AMD is

19.8 M

Large Global Market

By 2029, the intermediate to advanced AMD population will reach 96 million globally. In the US alone, it will affect 10.8 million people.

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Wet AMD 2024 US Market

15M

Patients

15.0B

Total US Market Revenue

VS.

Dry AMD 2029 US Market

10.8M

Patients

68.5B

Expected US Market Revenue

Tagline

Clinically significant, personally meaningful

i-Lumen’s proprietary dual waveform algorithm generates clinically significant vision improvement supporting a meaningful improvement in quality of life.

61.5%
with ≥10 letter improvement in BCVA by month 2
53.8%
maintained ≥10 letter improvement in BCVA through month 12
30.8%
with ≥15 letter improvement in BCVA at month 3

Restoring the electrophysiology of the retina

The i-Lumen AMD System® is focused on restoring the electrophysiology of the retina through a novel, non-invasive bioelectric stimulation improving vision for those with intermediate to advanced dry Age-related Macular Degeneration (AMD).

Proprietary edge

Our dual waveform has been refined over two decades of development and research in bioelectric stimulation.

Proven leadership

Our team has deep expertise in ophthalmology, electrophysiology, and bioelectric stimulation that drives product development and research.

Oxidative stress disrupts RPE function by reducing its transepithelial potential (TEP), a natural polarity across the cells, which contributes to retinal dysfunction and vision loss.

Boosting TEP improves RPE function restoring retinal homeostasis, photoreceptor function, and visual performance.

Tagline

$850M Strategic Acquisition Benchmark

In late 2025, Alcon completed a benchmark transaction, acquiring another pre-revenue, energy-based, device therapy to treat Dry-AMD for an estimated $850 million.

i-Lumen Delivers Superior Therapeutic Outcomes

Alcon's Valeda
Letter mean improvement
6.3
# of treatments
54
Duration
21 months
Acquisition
$850M
Feature text goes here
Feature text goes here
Feature text goes here
Feature text goes here
i-Lumen AMD System
Letter mean improvement
9.6
# of treatments
7
Duration
2 months
Acquisition
TBD
Feature text goes here
Feature text goes here
Feature text goes here
Feature text goes here
Exit strategy

Clear line-of-sight to strategic exit

i-Lumen’s clinically meaningful outcomes have generated significant interest from leading ophthalmology companies. The next major inflection point for i-Lumen is the release of primary endpoint data from its i-SIGHT2 Pivotal Study, currently targeted for early 2028.

Button
Button
Connect

Get in touch

Let's discuss what's possible together.

Thank you for your message. Someone will connect with you soon.
Oops! Something went wrong while submitting the form.

Email

Request our investor presentation and information about our Series B funding round
investors@i-lumen.com

Phone

Contact our team to discuss investment opportunities
+1 (833) 938-2020